NASDAQ:ANIP - ANI Pharmaceuticals Stock Price, Price Target & More

$60.64 -0.99 (-1.61 %)
(As of 04/20/2018 08:12 AM ET)
Previous Close$61.63
Today's Range$59.79 - $62.48
52-Week Range$42.23 - $74.70
Volume105,000 shs
Average Volume124,732 shs
Market Capitalization$722.78 million
P/E Ratio17.46
Dividend YieldN/A
Beta2.91

About ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals logoANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANIP
CUSIPN/A
Phone218-634-3500

Debt

Debt-to-Equity Ratio1.13%
Current Ratio3.36%
Quick Ratio2.39%

Price-To-Earnings

Trailing P/E Ratio17.46
Forward P/E Ratio11.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$176.84 million
Price / Sales4.02
Cash Flow$5.8874 per share
Price / Cash10.30
Book Value$14.99 per share
Price / Book4.05

Profitability

EPS (Most Recent Fiscal Year)$3.61
Net Income$-1,070,000.00
Net Margins-0.61%
Return on Equity23.41%
Return on Assets11.03%

Miscellaneous

Employees173
Outstanding Shares11,730,000

How to Become a New Pot Stock Millionaire

ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.06. The specialty pharmaceutical company had revenue of $47.30 million for the quarter, compared to analysts' expectations of $52.55 million. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. The company's revenue was up 23.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.84 EPS. View ANI Pharmaceuticals' Earnings History.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of $5.43-6.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.76. The company issued revenue guidance of $212-228 million, compared to the consensus revenue estimate of $219.98 million.

What price target have analysts set for ANIP?

3 Wall Street analysts have issued 12 month price objectives for ANI Pharmaceuticals' stock. Their predictions range from $56.00 to $82.00. On average, they expect ANI Pharmaceuticals' share price to reach $72.6667 in the next year. View Analyst Ratings for ANI Pharmaceuticals.

What are Wall Street analysts saying about ANI Pharmaceuticals stock?

Here are some recent quotes from research analysts about ANI Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (1/2/2018)
  • 2. Canaccord Genuity analysts commented, "We remain pessimistic about the company’s ability to execute a successful clinical trial required for FDA approval. The planned 2018 $10M cost-cutting initiative suggests to us that Eagle isn’t too confident either (and is generally in line with our expectations). Eagle’s other pipeline programs like fulvestrant and drug-induced hyperthermia are questionable and may require a few more years of development under a best case scenario, in our view. There was strangely no mention of the Alimta RTD PDUFA in October. Eagle also reiterated prior 2017 expense guidance of $50-$53M in SG&A (excluding stock based comp) and $26- $30M R&D (excluding stock-based comp). We note the company was previously reporting GAAP earnings so the change is slightly new. We also note that Eagle has expanded its borrowing capacity by $100M (suggesting to us that it may want to bring in new assets) but simultaneously announced an additional $100M buyback program." (8/9/2017)

Who are some of ANI Pharmaceuticals' key competitors?

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the folowing people:
  • Robert E. Brown Jr., Independent Chairman of the Board (Age 66)
  • Arthur S. Przybyl, President, Chief Executive Officer, Director (Age 60)
  • Stephen P. Carey, Chief Financial Officer, Vice President (Age 46)
  • James G. Marken, Vice President - Operations (Age 54)
  • Mark J. Ginski Ph.D., Vice President of Corticotropin Product Development
  • Karen Quinn Ph.D., Vice President - Corticotropin Regulatory Affairs
  • Robert W. Schrepfer, Vice President - New Business Development and Contract Manufacturing (Age 45)
  • Fred E. Holubow, Independent Director (Age 78)
  • Tracy L. Marshbanks Ph.D., Independent Director (Age 53)
  • Thomas A. Penn, Independent Director (Age 71)

Has ANI Pharmaceuticals been receiving favorable news coverage?

News stories about ANIP stock have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ANI Pharmaceuticals earned a coverage optimism score of 0.22 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 45.03 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $60.64.

How big of a company is ANI Pharmaceuticals?

ANI Pharmaceuticals has a market capitalization of $722.78 million and generates $176.84 million in revenue each year. The specialty pharmaceutical company earns $-1,070,000.00 in net income (profit) each year or $3.61 on an earnings per share basis. ANI Pharmaceuticals employs 173 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]


MarketBeat Community Rating for ANI Pharmaceuticals (ANIP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ANI Pharmaceuticals (NASDAQ:ANIP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for ANI Pharmaceuticals in the last 12 months. Their average twelve-month price target is $72.6667, suggesting that the stock has a possible upside of 19.83%. The high price target for ANIP is $82.00 and the low price target for ANIP is $56.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $72.6667$72.6667$71.00$67.3333
Price Target Upside: 19.83% upside20.31% upside11.62% upside12.02% upside

ANI Pharmaceuticals (NASDAQ:ANIP) Consensus Price Target History

Price Target History for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/27/2018Canaccord GenuitySet Price TargetBuy -> Buy$77.00 -> $82.00HighView Rating Details
7/4/2017GuggenheimReiterated RatingBuy$80.00LowView Rating Details
5/6/2017Roth CapitalSet Price TargetHold$56.00LowView Rating Details
8/5/2016OppenheimerBoost Price TargetOutperform$65.00 -> $71.00N/AView Rating Details
7/19/2016CitigroupUpgradeOutperform$65.00N/AView Rating Details
6/22/2016Raymond JamesInitiated CoverageStrong-Buy$68.00N/AView Rating Details
5/24/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

ANI Pharmaceuticals (NASDAQ:ANIP) Earnings History and Estimates Chart

Earnings by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP) Earnings Estimates

Current Year EPS Consensus Estimate: $5.17 EPS
Next Year EPS Consensus Estimate: $5.41 EPS

ANI Pharmaceuticals (NASDAQ ANIP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018Q4 17$1.02$1.08$52.55 million$47.30 millionViewN/AView Earnings Details
11/2/2017Q3 2017$0.99$1.11$48.12 million$48.16 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.79$0.98$43.20 million$44.80 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.70$0.74$39.63 million$36.60 millionViewListenView Earnings Details
3/2/2017Q4 2016$1.09$0.84$40.98 million$38.20 millionViewListenView Earnings Details
11/3/2016Q316$1.08$1.09$34.34 million$38.53 millionViewN/AView Earnings Details
8/4/2016Q216$0.77$1.11$27.63 million$31.30 millionViewN/AView Earnings Details
5/5/2016Q116$0.64$0.76$21.03 million$20.60 millionViewN/AView Earnings Details
2/23/2016Q415$0.60$0.52$18.13 million$18.04 millionViewN/AView Earnings Details
11/3/2015Q315$0.63$0.80$21.37 million$20.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.54$0.31$20.30 million$19.52 millionViewN/AView Earnings Details
5/5/2015Q115$0.56$0.53$19.86 million$18.80 millionViewN/AView Earnings Details
2/19/2015Q414$0.57$0.60$17.98 million$21.04 millionViewN/AView Earnings Details
11/3/2014Q314$0.43$0.59$14.60 million$17.40 millionViewN/AView Earnings Details
8/4/2014Q214($0.01)($0.21)$7.95 million$6.60 millionViewN/AView Earnings Details
5/5/2014Q115$0.32$0.33$11.40 million$10.90 millionViewN/AView Earnings Details
2/27/2014Q414$0.35$5.32 million$10.53 millionViewN/AView Earnings Details
2/18/2014Q4 2013$0.23$0.35$9.18 million$10.53 millionViewN/AView Earnings Details
11/7/2013$0.16$7.84 millionViewN/AView Earnings Details
8/9/2013Q2 2013($1.26)$6.15 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.54)ViewN/AView Earnings Details
3/1/2013Q4 2012($0.96)ViewN/AView Earnings Details
11/8/2012Q312($0.36)($0.27)ViewN/AView Earnings Details
8/1/2012Q2 2012($2.46)($2.18)ViewN/AView Earnings Details
5/8/2012Q1 2012($2.52)($3.24)ViewN/AView Earnings Details
3/13/2012Q4 2011($3.96)($2.16)ViewN/AView Earnings Details
11/9/2011Q3 2011($5.04)($4.39)ViewN/AView Earnings Details
7/25/2011Q2 2011($6.48)($5.76)ViewN/AView Earnings Details
5/10/2011Q1 2011($5.40)($7.20)ViewN/AView Earnings Details
3/16/2011Q4 2010($5.40)($6.48)ViewN/AView Earnings Details
11/12/2010Q3 2010($5.04)($5.76)ViewN/AView Earnings Details
8/12/2010Q2 2010($3.96)($6.12)ViewN/AView Earnings Details
5/14/2010Q1 2010($3.96)($6.84)ViewN/AView Earnings Details
11/9/2009Q3 2009($5.76)($5.79)ViewN/AView Earnings Details
8/7/2009Q2 2009($5.40)($6.12)ViewN/AView Earnings Details
5/11/2009Q1 2009($5.76)($5.40)ViewN/AView Earnings Details
3/16/2009Q4 2008($8.64)($1.80)ViewN/AView Earnings Details
11/10/2008Q3 2008($7.20)($8.64)ViewN/AView Earnings Details
8/11/2008Q2 2008($5.40)($7.92)ViewN/AView Earnings Details
5/9/2008Q1 2008($4.32)($4.68)ViewN/AView Earnings Details
3/17/2008Q4 2007($2.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ANI Pharmaceuticals (NASDAQ:ANIP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ANI Pharmaceuticals (NASDAQ ANIP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.10%
Institutional Ownership Percentage: 55.77%
Insider Trading History for ANI Pharmaceuticals (NASDAQ:ANIP)
Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ ANIP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018Tracy MarshbanksDirectorSell33,200$62.09$2,061,388.00View SEC Filing  
3/19/2018Daniel RaynorDirectorSell7,215$60.85$439,032.75View SEC Filing  
3/14/2018Arthur PrzybylInsiderSell40,000$61.83$2,473,200.00225,706View SEC Filing  
3/14/2018Daniel RaynorDirectorSell27,964$62.24$1,740,479.36View SEC Filing  
3/12/2018Tracy MarshbanksDirectorSell64,221$63.03$4,047,849.63View SEC Filing  
3/8/2018Tracy MarshbanksDirectorSell15,391$63.08$970,864.28View SEC Filing  
3/5/2018James G MarkenSVPSell4,177$61.92$258,639.8466,439View SEC Filing  
3/1/2018Robert W SchrepferSVPSell28,652$61.66$1,766,682.3241,590View SEC Filing  
8/22/2016Arthur PrzybylInsiderSell37,455$66.97$2,508,361.35200,788View SEC Filing  
8/8/2016Robert W SchrepferVPSell12,500$67.06$838,250.0017,362View SEC Filing  
12/18/2015James G MarkenVPSell3,500$43.26$151,410.0045,983View SEC Filing  
11/12/2015Arthur PrzybylCEOBuy2,500$40.95$102,375.00145,195View SEC Filing  
3/19/2015James G MarkenVPSell15,000$66.50$997,500.00View SEC Filing  
9/15/2014Ross J ManganoDirectorBuy3,000$27.49$82,470.00View SEC Filing  
9/9/2014Arthur PrzybylCEOBuy1,000$26.50$26,500.00View SEC Filing  
6/18/2014James G MarkenVPSell5,000$34.28$171,400.00View SEC Filing  
5/8/2014Tracy MarshbanksDirectorSell1,381$30.02$41,457.62View SEC Filing  
5/7/2014Ross ManganoDirectorBuy2,000$30.38$60,760.0023,914View SEC Filing  
3/21/2014Tracy MarshbanksDirectorSell21,767$31.42$683,919.14View SEC Filing  
3/20/2014Meridian Venture Partners Ii Lmajor shareholderSell20,922$32.12$672,014.64View SEC Filing  
3/19/2014Tracy MarshbanksDirectorSell25,358$33.68$854,057.44View SEC Filing  
3/18/2014Meridian Venture Partners Ii Lmajor shareholderSell60,540$34.07$2,062,597.80View SEC Filing  
3/13/2014Meridian Venture Partners Ii Lmajor shareholderSell87,723$32.48$2,849,243.04View SEC Filing  
11/7/2013Ross J ManganoDirectorBuy9,000$11.27$101,430.00View SEC Filing  
8/20/2013Ross J ManganoDirectorBuy10,000$7.47$74,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ANI Pharmaceuticals (NASDAQ ANIP) News Headlines

Source:
DateHeadline
ANI Pharmaceuticals (ANIP) Earns Buy Rating from GuggenheimANI Pharmaceuticals (ANIP) Earns Buy Rating from Guggenheim
www.americanbankingnews.com - April 19 at 11:52 PM
Tracy Marshbanks Sells 33,200 Shares of ANI Pharmaceuticals, Inc. (ANIP) StockTracy Marshbanks Sells 33,200 Shares of ANI Pharmaceuticals, Inc. (ANIP) Stock
www.americanbankingnews.com - April 19 at 7:20 PM
FDA OKs ANI Pharmas generic morphine oral solutionFDA OKs ANI Pharma's generic morphine oral solution
seekingalpha.com - April 18 at 5:07 PM
BRIEF-ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral SolutionBRIEF-ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral Solution
www.reuters.com - April 18 at 9:01 AM
ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral SolutionANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution
finance.yahoo.com - April 18 at 9:01 AM
ANI Pharmaceuticals (ANIP) Now Covered by Analysts at Canaccord GenuityANI Pharmaceuticals (ANIP) Now Covered by Analysts at Canaccord Genuity
www.americanbankingnews.com - April 15 at 9:45 AM
ANI Pharmaceuticals (ANIP) Rating Increased to Hold at BidaskClubANI Pharmaceuticals (ANIP) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 12 at 10:47 AM
ANI Pharmaceuticals (ANIP) Given Buy Rating at Canaccord GenuityANI Pharmaceuticals (ANIP) Given Buy Rating at Canaccord Genuity
www.americanbankingnews.com - April 7 at 12:31 PM
ANI Pharma (ANIP) Buys 23 ANDAs from IDT Australia, Ltd.ANI Pharma (ANIP) Buys 23 ANDAs from IDT Australia, Ltd.
www.streetinsider.com - April 4 at 3:39 PM
ANI Acquires 23 ANDAs from IDT Australia, Ltd.ANI Acquires 23 ANDAs from IDT Australia, Ltd.
finance.yahoo.com - April 4 at 9:04 AM
ANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of "Hold" by AnalystsANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 4 at 1:40 AM
ANI Pharmaceuticals (ANIP) Downgraded to "Hold" at ValuEngineANI Pharmaceuticals (ANIP) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 3 at 7:34 PM
Is ANI Pharmaceuticals Inc (NASDAQ:ANIP) A Financially Sound Company?Is ANI Pharmaceuticals Inc (NASDAQ:ANIP) A Financially Sound Company?
finance.yahoo.com - April 3 at 4:54 PM
ANI Pharmaceuticals (ANIP) Downgraded to Hold at BidaskClubANI Pharmaceuticals (ANIP) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM
Canaccord Genuity Analysts Give ANI Pharmaceuticals (ANIP) a $82.00 Price TargetCanaccord Genuity Analysts Give ANI Pharmaceuticals (ANIP) a $82.00 Price Target
www.americanbankingnews.com - March 24 at 5:43 PM
ANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 7,215 SharesANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 7,215 Shares
www.americanbankingnews.com - March 19 at 7:30 PM
Where ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Earnings Growth Stands Against Its IndustryWhere ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Earnings Growth Stands Against Its Industry
finance.yahoo.com - March 16 at 9:11 AM
ANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 27,964 SharesANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 27,964 Shares
www.americanbankingnews.com - March 14 at 7:11 PM
ANI Pharmaceuticals Inc (ANIP) Insider Sells $2,473,200.00 in StockANI Pharmaceuticals Inc (ANIP) Insider Sells $2,473,200.00 in Stock
www.americanbankingnews.com - March 14 at 7:10 PM
Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock?Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock?
www.zacks.com - March 14 at 9:44 AM
Tracy Marshbanks Sells 15,391 Shares of ANI Pharmaceuticals Inc (ANIP) StockTracy Marshbanks Sells 15,391 Shares of ANI Pharmaceuticals Inc (ANIP) Stock
www.americanbankingnews.com - March 12 at 10:28 PM
Tracy Marshbanks Sells 64,221 Shares of ANI Pharmaceuticals Inc (ANIP) StockTracy Marshbanks Sells 64,221 Shares of ANI Pharmaceuticals Inc (ANIP) Stock
www.americanbankingnews.com - March 12 at 10:28 PM
ANI Pharmaceuticals Inc (ANIP) Given Consensus Rating of "Hold" by BrokeragesANI Pharmaceuticals Inc (ANIP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 1:28 AM
Wired News – Aptose Biosciences Inked Exclusive License Agreement with OHM Oncology for APL-581Wired News – Aptose Biosciences Inked Exclusive License Agreement with OHM Oncology for APL-581
finance.yahoo.com - March 9 at 9:22 AM
ANI Pharmaceuticals (ANIP) Presents At Raymond James 39th Annual Institutional Investors Conference - SlideshowANI Pharmaceuticals (ANIP) Presents At Raymond James 39th Annual Institutional Investors Conference - Slideshow
seekingalpha.com - March 8 at 5:52 PM
Insider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 4,177 Shares of StockInsider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 4,177 Shares of Stock
www.americanbankingnews.com - March 7 at 6:50 PM
ANI Pharmaceuticals Inc (ANIP) Holdings Increased by Ranger Investment Management L.P.ANI Pharmaceuticals Inc (ANIP) Holdings Increased by Ranger Investment Management L.P.
www.americanbankingnews.com - March 6 at 2:11 PM
Insider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 28,652 Shares of StockInsider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 28,652 Shares of Stock
www.americanbankingnews.com - March 5 at 6:22 PM
ANI Pharmaceuticals (ANIP) Stock Rating Upgraded by ValuEngineANI Pharmaceuticals (ANIP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 3 at 6:07 PM
ANI Pharmaceuticals to Present at the Raymond James 39th Annual Institutional Investors ConferenceANI Pharmaceuticals to Present at the Raymond James 39th Annual Institutional Investors Conference
finance.yahoo.com - March 2 at 8:56 AM
Globeflex Capital L P Has $1.84 Million Position in ANI Pharmaceuticals Inc (ANIP)Globeflex Capital L P Has $1.84 Million Position in ANI Pharmaceuticals Inc (ANIP)
www.americanbankingnews.com - March 1 at 5:08 PM
Cortina Asset Management LLC Takes $6.09 Million Position in ANI Pharmaceuticals Inc (ANIP)Cortina Asset Management LLC Takes $6.09 Million Position in ANI Pharmaceuticals Inc (ANIP)
www.americanbankingnews.com - March 1 at 11:53 AM
ANI Pharmaceuticals (ANIP) CEO Arthur Przybyl on Q4 2017 Results - Earnings Call TranscriptANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 5:23 PM
ANI Pharmaceuticals, Inc. to Host Earnings CallANI Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - February 27 at 5:23 PM
ANI Pharmaceuticals (ANIP) Issues Quarterly  Earnings ResultsANI Pharmaceuticals (ANIP) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 27 at 11:30 AM
ANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 GuidanceANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance
finance.yahoo.com - February 27 at 9:01 AM
ANI Pharmaceuticals (ANIP) Issues FY18 Earnings GuidanceANI Pharmaceuticals (ANIP) Issues FY18 Earnings Guidance
www.americanbankingnews.com - February 27 at 8:48 AM
ANI Pharmaceuticals (ANIP) Downgraded by BidaskClub to "Sell"ANI Pharmaceuticals (ANIP) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - February 25 at 6:03 PM
ANI Pharmaceuticals (ANIP) Cut to "C+" at TheStreetANI Pharmaceuticals (ANIP) Cut to "C+" at TheStreet
www.americanbankingnews.com - February 25 at 12:56 PM
$52.49 Million in Sales Expected for ANI Pharmaceuticals Inc (ANIP) This Quarter$52.49 Million in Sales Expected for ANI Pharmaceuticals Inc (ANIP) This Quarter
www.americanbankingnews.com - February 25 at 2:02 AM
 Analysts Anticipate ANI Pharmaceuticals Inc (ANIP) to Announce $1.09 Earnings Per Share Analysts Anticipate ANI Pharmaceuticals Inc (ANIP) to Announce $1.09 Earnings Per Share
www.americanbankingnews.com - February 23 at 9:14 PM
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results and 2018 GuidanceANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results and 2018 Guidance
finance.yahoo.com - February 20 at 8:47 AM
Investors Are Undervaluing ANI Pharmaceuticals Inc (NASDAQ:ANIP) By 39.62%, Here Is My Intrinsic Value CalculationInvestors Are Undervaluing ANI Pharmaceuticals Inc (NASDAQ:ANIP) By 39.62%, Here Is My Intrinsic Value Calculation
finance.yahoo.com - February 14 at 9:27 AM
ANI Pharmaceuticals Inc (ANIP) Receives Consensus Rating of "Hold" from BrokeragesANI Pharmaceuticals Inc (ANIP) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 13 at 1:38 AM
 Analysts Anticipate ANI Pharmaceuticals Inc (ANIP) Will Post Earnings of $1.09 Per Share Analysts Anticipate ANI Pharmaceuticals Inc (ANIP) Will Post Earnings of $1.09 Per Share
www.americanbankingnews.com - February 6 at 9:12 PM
ANI Pharmaceuticals Inc (ANIP) Expected to Announce Earnings of $1.09 Per ShareANI Pharmaceuticals Inc (ANIP) Expected to Announce Earnings of $1.09 Per Share
www.americanbankingnews.com - January 21 at 1:16 AM
ANI Pharmaceuticals Inc (ANIP) Given Consensus Recommendation of "Buy" by AnalystsANI Pharmaceuticals Inc (ANIP) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 19 at 1:32 AM
ANI Pharmaceuticals (ANIP) Stock Rating Upgraded by BidaskClubANI Pharmaceuticals (ANIP) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 6 at 12:30 PM
INC Research (INCR) versus ANI Pharmaceuticals (ANIP) Head to Head ComparisonINC Research (INCR) versus ANI Pharmaceuticals (ANIP) Head to Head Comparison
www.americanbankingnews.com - January 4 at 7:30 PM
$1.09 EPS Expected for ANI Pharmaceuticals Inc (ANIP) This Quarter$1.09 EPS Expected for ANI Pharmaceuticals Inc (ANIP) This Quarter
www.americanbankingnews.com - January 4 at 3:28 AM

SEC Filings

ANI Pharmaceuticals (NASDAQ:ANIP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ANI Pharmaceuticals (NASDAQ:ANIP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ANI Pharmaceuticals (NASDAQ ANIP) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.